AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15383189 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol single inhaler therapy (160/4.5 microg, 2 inhalations once daily)
Number of subjects: 1890
Study 15383189 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol single inhaler therapy
Number of subjects: 1890
Study 15383189 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (160 microg, 2 inhalations twice daily) plus terbutaline 0.4 mg as needed
Number of subjects: 1890
Study 11480224 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 15 mg intravenously (gr. 1)
Number of subjects: 16
Study 11480224 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 30 mg orally (gr. 2)
Number of subjects: 16
Study 9737058 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry faces paired with shock
Number of subjects: 60
Study 9737058 — intervention group
Group type: COMPARATOR
Intervention: Angry faces paired with siren or nothing
Number of subjects: 60
Study 9737058 — intervention group
Group type: EXPERIMENTAL
Intervention: Women faces
Number of subjects: 60
Study 9737058 — intervention group
Group type: EXPERIMENTAL
Intervention: Men faces
Number of subjects: 60
Study 9737058 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial expectancies
Number of subjects: 60
Study 31656294 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection intraarticular anesthesia
Number of subjects: 48
Study 31656294 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural anesthesia
Number of subjects: 48
Study 28652065 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS‐SM group
Number of subjects: 25
Study 28652065 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 25517501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle therapy (Tracheostomy followed by ventilator-Assisted breathing with reverse trendelenburg position, early goal-directed hemodynamic support, enteral nutrition by nasointestinal tube, effective antibiotic usage and large doses of expectorants)
Number of subjects: 49
Study 25517501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle therapy
Number of subjects: 49
Study 25517501 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 49
Study 23558793 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of extension test (LOE test) in ACL-insufficient group
Number of subjects: 196
Study 23558793 — intervention group
Group type: COMPARATOR
Intervention: Normal maximum passive extension (MPE) in healthy population
Number of subjects: 196
Study 23558793 — intervention group
Group type: COMPARATOR
Intervention: Overall average side-to-side difference in MPE of the injured group
Number of subjects: 196
Study 19546268 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine
Number of subjects: 2837
Study 19546268 — intervention group
Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 2837
Study 17897912 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) treatment
Number of subjects: 220
Study 17897912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PE treatment)
Number of subjects: 220
Study 15030621 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate procedures with unbiased leader
Number of subjects: 0
Study 15030621 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate procedures with biased leader
Number of subjects: 0
Study 15030621 — intervention group
Group type: COMPARATOR
Intervention: Biased leader
Number of subjects: 0
Study 11929022 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithm based on artificial neural network (ANN) for joint location identification
Number of subjects: 110
Study 11929022 — intervention group
Group type: COMPARATOR
Intervention: Manual tracing by a trained radiologist
Number of subjects: 110
Study 9797798 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous doses of epoetin alfa (300, 450, 600, 900, 1200, 1350, 1800, and 2400 IU/kg)
Number of subjects: 2
Study 9797798 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple subcutaneous doses of epoetin alfa (150 IU/kg 3 times a week for 4 weeks)
Number of subjects: 2
Study 9797798 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple subcutaneous doses of epoetin alfa (600 IU/kg once per week for 4 weeks)
Number of subjects: 2
Study 9797798 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose regimens of epoetin alfa
Number of subjects: 2
Study 9797798 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral iron supplementation
Number of subjects: 2
Study 7635124 — intervention group
Group type: EXPERIMENTAL
Intervention: Headlight‐using motorcyclists
Number of subjects: 0
Study 7635124 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to headlight‐using motorcyclists
Number of subjects: 0
Study 7635124 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% of motorcyclists using their headlight
Number of subjects: 0
Study 7635124 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory conditions
Number of subjects: 0
Study 2696417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nyström nails
Number of subjects: 137
Study 2696417 — intervention group
Group type: COMPARATOR
Intervention: Scand screws
Number of subjects: 137
Study 636501 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 163
Study 636501 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial chemotherapy
Number of subjects: 163
Study 31650916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-open carpal tunnel release
Number of subjects: 13
Study 31650916 — intervention group
Group type: COMPARATOR
Intervention: Uni-portal endoscopic carpal tunnel release
Number of subjects: 13
Study 31650916 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both techniques
Number of subjects: 13
Study 28591523 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate completion lymph-node dissection
Number of subjects: 1934
Study 28591523 — intervention group
Group type: COMPARATOR
Intervention: Nodal observation with ultrasonography
Number of subjects: 1934
Study 26860020 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 48
Study 26860020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 48
Study 26860020 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 48
Study 23248028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA)
Number of subjects: 0
Study 23248028 — intervention group
Group type: COMPARATOR
Intervention: Combination of mycophenolate mofetil (MMF) and pulse dexamethasone (DEX)
Number of subjects: 0
Study 21300571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study 19076110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg/ml, 1 ml/kg with DEX 1 microg/kg
Number of subjects: 60
Study 19076110 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg/ml, 1 ml/kg
Number of subjects: 60
Study 17574137 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear tutorial layout
Number of subjects: 139
Study 17574137 — intervention group
Group type: COMPARATOR
Intervention: Web-style tutorial layout
Number of subjects: 139
Study 15051744 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride 125 mg every 12 hours for 3 days, then every 24 hours for 5 days
Number of subjects: 40
Study 15051744 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg coadministered on Day 8
Number of subjects: 40
Study 15051744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11605290 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporal shock wave therapy (ESWT)
Number of subjects: 30
Study 11605290 — intervention group
Group type: COMPARATOR
Intervention: X‐ray stimulation radiotherapy
Number of subjects: 30
Study 9738804 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + RT
Number of subjects: 46
Study 9738804 — intervention group
Group type: COMPARATOR
Intervention: surgery and RT
Number of subjects: 46
Study 8046475 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of dipyridamole (0.14 mg/kg/min for 4 min, total 0.56 mg/kg)
Number of subjects: 24
Study 8046475 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of dipyridamole (0.14 mg/kg/min for 6 min, total 0.84 mg/kg)
Number of subjects: 24
Study 8046475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of dipyridamole
Number of subjects: 24
Study 2927858 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral manual breast massage
Number of subjects: 213
Study 2927858 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pump stimulation
Number of subjects: 213
Study 2927858 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating pad stimulation
Number of subjects: 213
Study 2927858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 31115462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fulvic acid supplementation (0.6 g kg‐1)
Number of subjects: 720
Study 31115462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fulvic acid supplementation (1 g kg‐1)
Number of subjects: 720
Study 31115462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fulvic acid supplementation (0.2 g kg‐1)
Number of subjects: 720
Study 31115462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fulvic acid supplementation)
Number of subjects: 720
Study 28291866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin
Number of subjects: 15281
Study 28291866 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 15281
Study 26397109 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-length adaptive Cogmed WM training (CWMT; 45‐min/session)
Number of subjects: 97
Study 26397109 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened-length adaptive version of CWMT (15 min/session)
Number of subjects: 97
Study 26397109 — intervention group
Group type: COMPARATOR
Intervention: No training group (waitlist-control group)
Number of subjects: 97
Study 23412113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge (4 mg deliverable)
Number of subjects: 30
Study 23412113 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 30
Study 21466258 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic ice-cream containing Bifidobacterium lactis Bb12 and Lactobacillus acidophilus La5
Number of subjects: 40
Study 21466258 — intervention group
Group type: COMPARATOR
Intervention: Control ice-cream (placebo)
Number of subjects: 40
Study 19884613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus nicotine lozenge
Number of subjects: 1504
Study 19884613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 1504
Study 19884613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion
Number of subjects: 1504
Study 19884613 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion plus nicotine lozenge
Number of subjects: 1504
Study 19884613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1504
Study 19884613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1504
Study 17704968 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection for colorectal cancer
Number of subjects: 818
Study 17704968 — intervention group
Group type: COMPARATOR
Intervention: Open resection for colorectal cancer
Number of subjects: 818
Study 15182772 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 64
Study 15182772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 11777720 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5 mm scleral tunnel with PMMA IOL implantation
Number of subjects: 81
Study 11777720 — intervention group
Group type: COMPARATOR
Intervention: 3.5 mm clear corneal incision (CCI) with silicone foldable IOL implantation
Number of subjects: 81
Study 11777720 — intervention group
Group type: COMPARATOR
Intervention: 5.5 mm sutured CCI with PMMA IOL implantation
Number of subjects: 81
Study 9651636 — intervention group
Group type: EXPERIMENTAL
Intervention: Por La Vida (PLV) cancer screening intervention group
Number of subjects: 504
Study 9651636 — intervention group
Group type: COMPARATOR
Intervention: Community Living Skills control group
Number of subjects: 504
Study 7905143 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 58600
Study 2671414 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (40 mg)
Number of subjects: 40
Study 2671414 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (20 mg) and Phentolamine (0.5 mg)
Number of subjects: 40
Study 797539 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg clotrimazole troche, ten times a day
Number of subjects: 12
Study 797539 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg clotrimazole troche, ten times a day
Number of subjects: 12
Study 28525632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300 or 450 mg/day, twice daily)
Number of subjects: 193
Study 28525632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 27286894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant)
Number of subjects: 375
Study 27286894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant) only
Number of subjects: 375
Study 27286894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant) with other RVO treatment
Number of subjects: 375
Study 27286894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant) with ≥2 DEX implants
Number of subjects: 375
Study 24674676 — intervention group
Group type: EXPERIMENTAL
Intervention: Renagel (Genzyme manufacturer)
Number of subjects: 28
Study 24674676 — intervention group
Group type: COMPARATOR
Intervention: Generic equivalent (EMS manufacturer)
Number of subjects: 28
Study 24674676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sevelamer tablet forms
Number of subjects: 28
Study 22809563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal-left anterior descending shunt
Number of subjects: 38
Study 22809563 — intervention group
Group type: COMPARATOR
Intervention: External tournique occlusion
Number of subjects: 38
Study 20430577 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 20430577 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 0
Study 20430577 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ETN+MTX
Number of subjects: 0
Study 20430577 — intervention group
Group type: EXPERIMENTAL
Intervention: German etanercept registry
Number of subjects: 0
Study 17591482 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal report (VR)
Number of subjects: 80
Study 17591482 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard verbal report followed by a computer-generated endoscopy report (VR+WR)
Number of subjects: 80
Study 15649160 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 11.2 microg.kg(‐1)
Number of subjects: 45
Study 15649160 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 15 microg.kg(‐1)
Number of subjects: 45
Study 15649160 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 20 microg.kg(‐1)
Number of subjects: 45
Study 15649160 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (11.2, 15, 20 microg.kg(‐1))
Number of subjects: 45
Study 12107208 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg rhGH/kg body weight per day
Number of subjects: 6
Study 12107208 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 microg rhGH/kg body weight per day
Number of subjects: 6
Study 12107208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10073860 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pacing mode
Number of subjects: 10
Study 10073860 — intervention group
Group type: COMPARATOR
Intervention: Inactive pacing mode
Number of subjects: 10
Study 10073860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active and inactive pacing modes
Number of subjects: 10
Study 7720945 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg at 8:00 and 0.75 mg at 10:00 and 12:00 A.M.)
Number of subjects: 0
Study 7720945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1974484 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (ARG) 0.5 g/kg infused i.v. over 30 min with GHRH 1 microgram/kg i.v.
Number of subjects: 15
Study 1974484 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (ARG) 0.5 g/kg infused i.v. with Pyridostigmine (PD) 60 mg orally
Number of subjects: 15
Study 1974484 — intervention group
Group type: COMPARATOR
Intervention: GHRH 1 microgram/kg i.v. alone
Number of subjects: 15
Study 1974484 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PD and GHRH administration
Number of subjects: 15
Study 7237220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose droperidol (0.005 mg x kg‐1)
Number of subjects: 200
Study 31810943 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a self‐expandable metal stent (Group 1)
Number of subjects: 46
Study 31810943 — intervention group
Group type: COMPARATOR
Intervention: Primary tumor resection (Group 2)
Number of subjects: 46
Study 28447625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements (combination pill)
Number of subjects: 176
Study 28447625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 26219694 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + OPV0
Number of subjects: 7012
Study 26219694 — intervention group
Group type: COMPARATOR
Intervention: BCG only
Number of subjects: 7012
Study 26219694 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + OPV0 (boys)
Number of subjects: 7012
Study 26219694 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + OPV0 (girls)
Number of subjects: 7012
Study 26219694 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + OPV0 (enrolled within first 2 days)
Number of subjects: 7012
Study 26219694 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + OPV0 (before OPV campaigns)
Number of subjects: 7012
Study 24419064 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc-containing regimens
Number of subjects: 938
Study 21777972 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT (200 mg/kg intravenous cyclophosphamide, 6.5 mg/kg intravenous rabbit antithymocyte globulin)
Number of subjects: 19
Study 21777972 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (1.0 g/m² intravenous once per month for 6 months)
Number of subjects: 19
Study 21777972 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT (after switching from cyclophosphamide)
Number of subjects: 19
Study 19302017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 0
Study 19302017 — intervention group
Group type: COMPARATOR
Intervention: Unboosted atazanavir
Number of subjects: 0
Study 17560476 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) ACL reconstruction using 4-strand semitendinosus tendon (ST) with EndoButton femoral fixation and anchor staple tibial fixation
Number of subjects: 68
Study 17560476 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle (SB) ACL reconstruction using 4-strand semitendinosus tendon (ST) with EndoButton femoral fixation and anchor staple tibial fixation
Number of subjects: 68
Study 15968602 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT imaging
Number of subjects: 303
Study 15968602 — intervention group
Group type: COMPARATOR
Intervention: Planar imaging
Number of subjects: 303
Study 12536495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) administered by hypodermic injection for four weeks
Number of subjects: 24
Study 12536495 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LMWH treatment)
Number of subjects: 24
Study 9922069 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend to Friend intervention (health professional talk, small group discussions, assistance in obtaining mammograms)
Number of subjects: 41
Study 9922069 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control)
Number of subjects: 41
Study 8771838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined examinations (urosonography, USG and CT)
Number of subjects: 86
Study 8771838 — intervention group
Group type: COMPARATOR
Intervention: Individual imaging techniques
Number of subjects: 86
Study 3453385 — intervention group
Group type: EXPERIMENTAL
Intervention: Accutracker
Number of subjects: 50
Study 3453385 — intervention group
Group type: COMPARATOR
Intervention: Clinician
Number of subjects: 50
Study 3453385 — intervention group
Group type: COMPARATOR
Intervention: Strip chart recorder
Number of subjects: 50
Study 29989430 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming group (n=36)
Number of subjects: 65
Study 29989430 — intervention group
Group type: COMPARATOR
Intervention: Free-play group (n=29)
Number of subjects: 65
Study 25214362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure and Harmonic Scalpel
Number of subjects: 180
Study 25214362 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 180
Study 26224298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-seafood intervention
Number of subjects: 20
Study 26224298 — intervention group
Group type: COMPARATOR
Intervention: Nonseafood intervention
Number of subjects: 20
Study 22922591 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF5074 200 mg/d for 14 d
Number of subjects: 48
Study 22922591 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF5074 400 mg/d for 14 d
Number of subjects: 48
Study 22922591 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF5074 600 mg/d for 14 d
Number of subjects: 48
Study 22922591 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF5074 (all doses)
Number of subjects: 48
Study 16621882 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography and appropriate intervention (n = 895)
Number of subjects: 1810
Study 16621882 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided conservative strategy (n = 915)
Number of subjects: 1810